









Markets
/
Stocks
/
nasdaq-onc
/

Beigene Ltd

ONC

314.850USD

-2.000-0.63%

Close 10/29, 16:00（ET）Quotes delayed by 15 min

31.80BMarket Cap

LossP/E TTM



Beigene Ltd

314.850

-2.000-0.63%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Beigene Ltd

Currency: USD Updated: 2025-10-29

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Beigene Ltd's Score

Industry at a Glance

Industry Ranking

39 / 407

Overall Ranking

126 / 4623

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 24 analysts

Buy

Current Rating

371.510

Target Price

+17.25%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Beigene Ltd Highlights

StrengthsRisks

BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 169.10% year-on-year.

Undervalued

The company’s latest PE is -187.43, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 35.66M shares, decreasing 22.19% quarter-over-quarter.

Held by PRIMECAP Management

Star Investor PRIMECAP Management holds 5.09M shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-29

The company's current financial score is 9.48, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 1.32B, representing a year-over-year increase of 41.56%, while its net profit experienced a year-over-year increase of 178.34%.

Score

Industry at a Glance

Previous score

9.48

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Beigene Ltd's Company Valuation

Currency: USD Updated: 2025-10-29

The company’s current valuation score is 7.49, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -187.43, which is -96.88% below the recent high of -5.86 and -11.52% above the recent low of -209.02.

Score

Industry at a Glance

Previous score

7.49

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 39/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-29

The company’s current earnings forecast score is 8.43, which is higher than the Biotechnology & Medical Research industry's average of 8.01. The average price target for Beigene Ltd is 373.00, with a high of 448.00 and a low of 250.00.

Score

Industry at a Glance

Previous score

8.43

Change

Support & Resistance

No Data

Analyst Rating

Based on 24 analysts

Buy

Current Rating

371.510

Target Price

+17.25%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

520

Total

Median

Average

Company name

Ratings

Analysts

BeOne Medicines AG

ONC

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-29

The company’s current price momentum score is 6.78, which is higher than the Biotechnology & Medical Research industry's average of 6.54. Sideways: Currently, the stock price is trading between the resistance level at 344.77 and the support level at 295.47, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.80

Change

-0.02

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-2.404

Sell

RSI(14)

44.351

Neutral

STOCH(KDJ)(9,3,3)

55.363

Buy

ATR(14)

8.895

Low Volatility

CCI(14)

-41.759

Neutral

Williams %R

66.464

Sell

TRIX(12,20)

-0.260

Sell

StochRSI(14)

74.937

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

313.594

Buy

MA10

315.028

Sell

MA20

324.829

Sell

MA50

325.695

Sell

MA100

301.491

Buy

MA200

271.192

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-29

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.21. The latest institutional shareholding proportion is 32.52%, representing a quarter-over-quarter decrease of 43.48%. The largest institutional shareholder is PRIMECAP Management, holding a total of 5.09M shares, representing 4.64% of shares outstanding, with 11.12% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Amgen Inc

18.94M

Baker Bros. Advisors LP

8.80M

PRIMECAP Management Company

Star Investors

5.09M

+0.65%

Capital International Investors

4.89M

-4.05%

Fidelity Management & Research Company LLC

3.41M

+1.54%

HHLR Advisors, Ltd.

1.03M

Temasek Holdings Pte. Ltd.

1.01M

+1.68%

T. Rowe Price International Ltd

931.90K

-28.38%

Citadel Advisors LLC

537.16K

-45.31%

Invus Public Equities Advisors, LLC

509.99K

+2.27%

Risk Assessment

Currency: USD Updated: 2025-10-29

The company’s current risk assessment score is 6.87, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.31. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.